Karyopharm Therapeutics (KPTI)
(Real Time Quote from BATS)
$4.20 USD
+0.17 (4.22%)
Updated Aug 7, 2025 11:40 AM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, Karyopharm Therapeutics Inc. has a market cap of $34.82M, which represents its share price of $4.03 multiplied by its outstanding shares number of 8.64M. As a small-cap company, KPTI's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
KPTI 4.20 +0.17(4.22%)
Will KPTI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KPTI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KPTI
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
KPTI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
Other News for KPTI
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 | KPTI Stock News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KPTI ...
JPMorgan Chase & Co. Expands Stake in Karyopharm Therapeutics Inc.
KPTI Downgraded to Neutral by HC Wainwright & Co. | KPTI Stock News
KPTI Downgraded by Analyst Amid Financial Concerns | KPTI Stock News